Throughout history, healthcare has been driven by one overarching goal: to develop treatments that are more accurate and effective for everyone. In today's world, the combination of advanced genetic sequencing, big-data analytics and fast supercomputing is helping healthcare professionals refine and individualize treatments. Known as "precision (or personalized) medicine", this advanced technology delivers a highly specific treatment suited to every individual patient. Healthcare professio...

May 16 the webinar or to register. ABOUT MGI MGI Tech Co., Ltd. (MGI), an affiliate of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced ...

With a mission to lead life science through intelligent innovation and to develop and promote advanced life science tools for future health care in Africa, MGI, a company committed to being a world-leading life science innovator, has been supporting the advancement of genomics in Africa. To support and promote outstanding genomics in Africa, MGI hosted the MGI's Africa Sequencing Challenge which provided a chance for African Scientists all over the continent to win either a MGI DNBSEQ™ ...

2. The jury also found that Illumina's asserted claims of all three patents are invalid. For Chinese version statement: https://www.mgi-tech.com/news/464/

Shenzhen, China, 27th April, 2022 - MGI, a company committed to being a world-leading life science innovator, today introduced the new commercial sequencing chemistry, HotMPS*. This new sequencing chemistry has been developed to be used on MGI's DNBSEQ-G400** sequencer and will be available in selected countries from April 2022. MGI's HotMPS High-throughput Sequencing Kit* Used on DNBSEQ-G400 Sequencer** HotMPS* is built upon the combinatorial Probe Anchor Synthesis (cPAS) technology found...

The partnership will address some critical issues in pharmacogenetic assay through sequencing workflows improvement – MGI, a company committed to being a world-leading life science innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low coverage whole genome sequencing for risk prediction and pharmacogenomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI's sequencing devices and products*. MGI's High-throughput Genetic Sequencer* ...